250 results on '"Delord J"'
Search Results
2. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages
3. Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial
4. Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine
5. 490P Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
6. LBA33 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase II study
7. LBA36 A randomised phase II study to evaluate the efficacy and safety of androgen deprivation therapy (ADT) vs chemotherapy (CT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancers
8. Prediction of long-term cumulative incidences based on short-term parametric model for competing risks: application in early breast cancer
9. An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma
10. 173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2
11. Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity
12. MA16.01 Subsequent Systemic Therapy After Lurbinectedin Discontinuation in Patients With Small-cell Lung Cancer
13. 983P Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor
14. 898P Locoregional vs. distant relapse: Impact on survival in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immunotherapy
15. 552P Reasons of screening failure during the 28-day screening period in patients identified for inclusion in phase I trials and their outcome
16. 896P Long-responders to ICI in R/M-HNSCC: A retrospective multicentric French cohort
17. Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors
18. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phase
19. Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study
20. T-DM1-related telangiectasias: a potential role in secondary bleeding events
21. OC-0333 Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial
22. LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer
23. 137P VEGFR-3 expression profiling by histology and mRNA signature to classify patient population for the selective VEGFR-3 inhibitor EVT801
24. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment
25. MO01.09 Phase 2 Basket Trial of Lurbinectedin in Small-Cell Lung Cancer (SCLC): Analysis of Efficacy by Baseline Characteristics
26. MO01.10 Activity of Lurbinectedin in Second-line SCLC Patients Who Are Candidates for Platinum Rechallenge
27. MO01.08 Phase 2 Basket Trial of Lurbinectedin in Second-line SCLC: Characteristics and Outcomes in Treatment Responders
28. 63MO TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor microenvironement (TME) and drives antitumor responses in human papillomavirus (HPV)+ malignancies
29. LBA39 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck
30. 1784P Activity of lurbinectedin in second-line SCLC patients candidates for platinum re-challenge
31. 162TiP A phase I study evaluating BI 765063, a first in class selective myeloid SIRPa inhibitor, as standalone and in combination with BI 754091, a programmed death-1 (PD-1) inhibitor, in patients with advanced solid tumours
32. 676P ATHENA: A multicenter phase II of atezolizumab (A) and bevacizumab (B) in patients (pts) with recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M HNSCC) - The HPV-negative cohort
33. The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non–small-cell lung cancer: a real-life retrospective study
34. ACCESS TO EARLY CLINICAL TRIALS IN OLDER PATIENTS IN FRANCE: AN ANALYSIS OF THE EGALICAN 2 STUDY
35. Improving patient selection for immuno-oncology phase I trials: An external validation of five prognostic scores at Claudius Regaud Institute of Toulouse, Oncopôle (IUCT-O)
36. Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
37. Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
38. Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies
39. A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors
40. Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158
41. PRODIGE67_UCGI33 ARION: Association of radiochemotherapy and immunotherapy for the treatment of unresectable oesophageal cancer: A comparative randomized phase II trial
42. Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study
43. P1.12-03 Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring ≥30 Days After Last Platinum Dose
44. Abstract OT3-05-03: MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody)–Additional breast cancer cohorts
45. Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
46. Iron-Catalyzed Minisci Type Acetylation of N -Heteroarenes Mediated by CH(OEt)3 /TBHP
47. Phase I/II study of FGF401 in adult patients (pts) with hepatocellular carcinoma (HCC) or solid tumors and positive FGFR4/KLB expression
48. The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non–small-cell lung cancer: a real-life retrospective study.
49. TOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&Neck Group and the GORTEC
50. KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.